Molecular imaging is central to the theranostics market because it allows healthcare providers to visualize disease activity and biological targets within the body. This information can support diagnosis, treatment selection, response monitoring, and follow-up care.

PET and MRI are among the most important imaging technologies in theranostics. PET can identify metabolic or molecular activity, while MRI provides detailed anatomical and tissue information. Combined imaging approaches can help clinicians understand both the location and behavior of disease.

In oncology, molecular imaging may help identify tumors that express a relevant biological target. This can support the selection of patients for targeted treatments and help determine whether a therapy is working over time. In neurology, imaging and biomarkers may help researchers study neurodegenerative conditions and identify disease changes earlier.

The increasing availability of imaging data is creating demand for AI-supported analysis. Algorithms can help identify patterns, quantify lesions, compare scans over time, and support workflow prioritization. These systems must be clinically validated and used under appropriate professional supervision.

Access to advanced imaging remains uneven. Large hospitals and cancer centers are more likely to have PET, MRI, molecular imaging expertise, and specialist radiology support. Smaller facilities may rely on referral networks, tele-radiology, and regional diagnostic centers.

The future market will depend on better imaging access, new targeted agents, improved software, and stronger integration between imaging, pathology, genomics, and treatment planning.

Read more: Theranostics Market

FAQs

Q1. Why is molecular imaging important in theranostics?
It helps identify disease activity and supports more targeted treatment planning.

Q2. Which imaging methods are commonly used?
PET, MRI, and combined imaging systems are important in theranostic workflows.

Tags: molecular imaging, PET scan, MRI diagnostics, cancer imaging, precision oncology